In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer
Host: John L. Marshall, MD
\n\n\n \n
Gastric and gastroesophageal junction cancers are the third most common cause of cancer deaths globally. In this Chairman\u2019s Perspective, Dr. John Marshall breaks down the latest data from the 2023 World Congress on GI Cancer in Barcelona, Spain, so you can more effectively treat your patients.